Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

@article{Douillard2006AdjuvantVP,
  title={Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.},
  author={J. Y. Douillard and Rafael Rosell and Mario De Lena and Francesco Carpagnano and Rodryg Adam Ramlau and Jose Luis Gonz{\'a}les-Larriba and Tomasz Grodzki and Jose R. Pereira and Alain Le Groumellec and Vito Lorusso and Claude Clary and Antonio J. Torres and Jabrail Dahabreh and Pierre Jean Souquet and Julio Astudillo and Pierre Fournel and Angel Artal-Cort{\'e}s and Jacek Jassem and Leona Koubkov{\'a} and Patricia His and Marcello Riggi and Patrick Hurteloup},
  journal={The Lancet. Oncology},
  year={2006},
  volume={7 9},
  pages={719-27}
}
BACKGROUND Whether adjuvant chemotherapy improves survival of patients with non-small-cell lung cancer (NSCLC) is not known. We aimed to compare the effect of adjuvant vinorelbine plus cisplatin versus observation on survival in patients with completely resected NSCLC. METHODS 840 patients with stage IB-IIIA NSCLC from 101 centres in 14 countries were randomly assigned to observation (n=433) or to 30 mg/m(2) vinorelbine plus 100 mg/m(2) cisplatin (n=407). Postoperative radiotherapy was not… CONTINUE READING
Highly Influential
This paper has highly influenced 34 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 428 extracted citations

Similar Papers

Loading similar papers…